| Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events (NCT00346242) | Novartis Pharmaceuticals | 2004-03-01 |
| L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia (NCT00125788) | Emmaus Medical, Inc. | 2004-03-01 |
| L-Glutamine Therapy for Sickle Cell Anemia (NCT00586209) | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 2004-02-06 |
| Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO (NCT00578292) | Baylor College of Medicine | 2004-02-01 |
| Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study) (NCT00502788) | Carelon Research | 2003-05-01 |
| Stem Cell Transplant for Hemoglobinopathy (NCT00176852) | Masonic Cancer Center, University of Minnesota | 2002-06-01 |
| A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen (NCT00427661) | University of Pittsburgh | 2002-06-01 |
| Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia (NCT00034528) | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-09-01 |
| Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies (NCT00040469) | Baylor College of Medicine | 2000-08-01 |
| Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies (NCT00040417) | Baylor College of Medicine | 2000-08-01 |
| Combination Iron Chelation Therapy (NCT00004982) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1998-12-01 |
| Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone (NCT00000588) | Case Western Reserve University | 1989-06-05 |
| Deferoxamine for the Treatment of Hemochromatosis (NCT00001203) | National Heart, Lung, and Blood Institute (NHLBI) | 1985-04-22 |
| Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis (NCT00000595) | National Heart, Lung, and Blood Institute (NHLBI) | 1978-01-01 |